Trial Profile
A multi-centre, double-blind, placebo controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of KRP203 in subjects with moderately active refractory ulcerative colitis.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Mocravimod (Primary)
- Indications Ulcerative colitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis
- 24 May 2016 Interim results (n = 27) presented at the Digestive Disease Week 2016.
- 19 Jun 2011 New source added and integrated (ClinicalTrials.gov, NCT01375179).
- 19 Jun 2011 Planned end date changed from 31 Jan 2012 to 31 Dec 2012 as reported by ClinicalTrials.gov.